Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidotes for organophosphate toxicity, such as atropine sulfate, are primarily administered via injection, which is inconvenient, costly, and often unavailable in low-income areas, especially during emergency situations.
Innovation Solution
Development of rapidly-disintegrating sublingual tablets (RDSTs) formulation for atropine sulfate, optimized with pH modification and penetration enhancers like sodium dodecyl sulfate (SDS), chitosan, bile salts, and palmitoyl-L carnitine chloride, to enhance sublingual permeability and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If atropine sulfate is administered via injection, then the drug delivery is reliable and fast, but it is inconvenient, costly, and often unavailable in low-income areas
Solution Approach 1:
The patent replaces the mechanical injection system (syringe, needle, auto-injector) with a chemical dissolution system. The atropine sulfate is formulated in rapidly-disintegrating sublingual tablets that dissolve in saliva, eliminating the need for mechanical injection devices and enabling administration in resource-limited settings while maintaining reliable drug delivery through the sublingual route
Solution Approach 2:
The patent introduces saliva as an intermediary medium to deliver the drug. Instead of direct parenteral injection, the atropine sulfate tablets dissolve in saliva, which then facilitates drug absorption through the sublingual mucosa. This intermediary approach maintains fast and reliable drug delivery while greatly improving convenience and accessibility
2Speed
If conventional tablets are used, then the formulation is simple and cost-effective, but they disintegrate slowly and do not provide rapid drug absorption
Solution Approach 1:
The patent changes the physical and chemical parameters of the tablet formulation to achieve rapid disintegration. Specifically, it uses superdisintegrants (cross-linked carboxymethyl cellulose sodium, sodium starch glycolate), alkalizing agents (sodium bicarbonate, calcium carbonate) to modify pH and enhance disintegration, and optimizes the binder content and particle size distribution. These parameter changes enable the tablet to disintegrate within seconds in sublingual administration
Solution Approach 2:
The patent employs a composite formulation containing multiple functional ingredients: atropine sulfate (active ingredient), microcrystalline cellulose (filler), superdisintegrants (cross-linked carboxymethyl cellulose sodium, sodium starch glycolate), alkalizing agents (sodium bicarbonate, calcium carbonate), and binders (starch, polyvinylpyrrolidone). This composite material system works synergistically to achieve rapid disintegration and absorption while maintaining formulation simplicity for manufacturing
3Reliability
If pH modification and penetration enhancers are added to enhance sublingual permeability, then drug absorption is improved, but the formulation complexity increases
Solution Approach 1:
The patent modifies the pH parameter of the formulation by incorporating alkalizing agents (sodium bicarbonate, calcium carbonate) to create a more favorable pH environment for atropine sulfate dissolution and absorption. It also incorporates penetration enhancers (sodium dodecyl sulfate, chitosan, bile salts, palmitoyl-L carnitine chloride) at optimized concentrations to enhance mucosal permeability. These parameter changes significantly improve sublingual absorption while the concentrations are kept within safe and effective ranges
Solution Approach 2:
The patent applies penetration enhancers and pH modifiers locally at the sublingual administration site rather than systemically. The formulation is designed to release these agents specifically in the sublingual cavity, where they locally enhance permeability without requiring high overall concentrations. This localized approach improves absorption efficiency while minimizing formulation complexity and potential side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RDSTs provide a user-friendly, convenient, and cost-effective alternative for administering atropine sulfate, potentially improving treatment outcomes for acute organophosphate toxicity by facilitating rapid drug absorption and bypassing hepatic first-pass metabolism.
Implementation Method 1
optimized with pH modification and penetration enhancers like sodium dodecyl sulfate (SDS), chitosan, bile salts, and palmitoyl-L carnitine chloride, to enhance sublingual permeability and absorption
Implementation Method 2
The RDSTs provide a user-friendly, convenient, and cost-effective alternative for administering atropine sulfate, potentially improving treatment outcomes for acute organophosphate toxicity by facilitating rapid drug absorption
Data Source
AI summary
The invention provides atropine sulfate (AS) rapidly-disintegrating sublingual tablets (RDSTs) of improved formulation in a sublingual dosage form and methods for therapeutic use of the AS RDSTs for treatment of organophosphate (OP) exposure and acute toxicity. The AS RDSTs provide an alternative easy-to-use dosage form for the management of organophosphate toxicity. Additionally, the invention provides methods for improved formulation and quality evaluation of the atropine sulfate rapidly-disintegrating sublingual tablets.